ORIGINAL ARTICLEFREE PREVIEW 24-Hour Urinary Sodium and Potassium Excretion and Cardiovascular Risk Yuan Ma, Feng J. He, Qi Sun, et al N Engl J Med 2022; 386:252-263DOI: 10.1056/NEJMoa2109794 Abstract BACKGROUND The relation between sodium intake and cardiovascular disease remains controversial, owing in part to inaccurate assessment of sodium intake. Assessing 24-hour urinary excretion over a period of multiple days is considered to be an accurate metho...

ONLINE FIRST (FREE ACCESS) LATEST ARTICLES OriginalUndocumented migrants in French intensive care units in 2011–2018: retrospective nationwide studyHraiech S. et al. Systematic Review Effect of prone positioning on survival in adult patients receiving venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: a systematic review and meta-analysisPapazian L. et al. EditorialTowards evidence-based staffing: the promise a...

ICU Management & Practice, Volume 21 - Issue 6, 2021 Management of Pulmonary Embolism in the Intensive Care Unit Pulmonary embolism is a reason for admission to the Intensive Care Unit and this complication in hospitalised patients is associated with high morbidity and mortality. The identification and management of pulmonary embolism is a challenge for doctors. Introduction Pulmonary Embolism (PE) is the third cardiovascular cause of death since its ...

ARTICLES|ONLINE FIRST Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial E Wesley Ely, Athimalaipet V Ramanan, Cynthia E Kartman, et al Lancet Respir Med Published:February 03, 2022 DOI:https://doi.org/10.1016/S2213-2600(22)00006-6 Summary Background ...

ICU Management & Practice, Volume 21 - Issue 6, 2021 Anaemia in the Critically Ill: What is the Major Culprit? Anaemia is commonly encountered in the critically ill and is associated with poor outcomes. The cause is multifactorial and includes high hepcidin levels and a blunted response to erythropoietin. Anaemia is defined by haemoglobin (Hb) < 12 g/dL for women and Hb below 13 g/dL for men, according to the WHO (1968). Anaemia is a prevalent conditi...

ORIGINAL ARTICLEFREE PREVIEW SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection Paul Feuerstadt, Thomas J. Louie, Bret Lashner, et al N Engl J Med 2022; 386:220-229DOI: 10.1056/NEJMoa2106516 Abstract BACKGROUND Current therapies for recurrent Clostridioides difficile infection do not address the disrupted microbiome, which supports C. difficile spore germination into toxin-producing bacteria...

ARTICLES| VOLUME 22, ISSUE 2, P196-208, FEBRUARY 01, 2022 Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial ShengLi Xia, YunTao Zhang, YanXia Wang, et al Lancet Infect Dis 2022; 22: 196-208 Summary Background Although SARS-CoV-2 infection often causes milder symptoms in children and adolescents, young people might still play a k...

ICU Management & Practice, Volume 21 - Issue 6, 2021 Nutritional Care for Patients with COVID-19 Requiring Intensive Care Recommendations for the management of nutrition of COVID-19 patients provide guidelines for nutrition risk screening, requirements, timing, route and mode of feeding, monitoring, equipment and workforce requirements. The worldwide pandemic of COVID-19 continues to impact all aspects of intensive care unit (ICU) management, including n...

ORIGINAL ARTICLEFREE PREVIEW Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants Laura L. Hammitt, Ron Dagan, Yuan Yuan, et al N Engl J Med 2022; 386:837-846DOI: 10.1056/NEJMoa2110275 Abstract BACKGROUND Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV fusion protein that has an extended half-life. The efficacy and s...

ORIGINAL ARTICLE Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines Nick Andrews, Elise Tessier, Julia Stowe, et al N Engl J Med January 12, 2022DOI: 10.1056/NEJMoa2115481 Abstract BACKGROUND Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), have been used since December 2020 in the United Kingdom. Real-world data have shown the vaccines ...